HIV Facial Lipoatrophy and Bio-Alcamid Equals a High Risk

Patients with HIV-related facial lipoatrophy that receive Bio-Alcamid (polyalkylimide) filler experience a high risk of infection.

Studies that once supported the use of Bio-Alcamid are now considered erroneous and Polymekon–the company that manufactured it—went out of business.

Doctors have noticed that some patients develop infections years after the treatment.

Read more:

High infection risk with HIV lipoatrophy filler Bio-Alcamid